Roche (RHHBY.US) new breast cancer drug Wilserdly approved by FDA: analysts forecast peak annual sales of up to 14.5 billion US dollars

Zhitongcaijing · 1d ago

The Zhitong Finance App learned that Roche Holdings (RHHBY.US)'s new oral breast cancer medication has been approved by US regulators, clearing the way for this drug that pharmaceutical companies are hoping to change the way the disease is treated.

The US Food and Drug Administration (FDA) said on Monday that it has approved this treatment plan, called Wilserdly, to be used in combination with a targeted cancer therapy to treat locally advanced or metastatic breast cancer driven by a genetic mutation, and is suitable for patients whose cancer has recurred or progressed after previous treatment.

The drug is taken once a day until the disease worsens or the patient develops unacceptable toxic complications. Approval is accompanied by a warning label: risk of bradycardia (i.e. dangerous bradycardia), and fetal toxicity in pregnant women.

Roche's move is aimed at seizing an emerging class of drugs that may reshape the most common breast cancer treatment pattern. Wilserdly's success or failure is critical for the Swiss pharmaceutical company — analysts predict the drug will become a blockbuster drug with annual sales peaking between $2.5 billion and $14.5 billion.

Affected by the approval news, Roche Holdings' American Depositary Receipts (ADR) rose 1.2% at 3:32 p.m. New York time.

The FDA said that this approval is based on the drug compared to an older combination regimen, which can delay the median progression of cancer by 4.5 months. However, regulators also pointed out that it is still too early to determine whether the drug can prolong the overall survival of patients.

A Roche spokesperson did not immediately respond to questions about pricing.